Ellevest, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Ellevest, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 24, 2022	SELL	$30.74 - $49.16 $922 - $1,474	-30 Closed	0 $0
Q3 2021 Oct 19, 2021	SELL	$31.4 - $69.84 $94 - $209	-3 Reduced 9.09%	30 $1,000
Q2 2021 Jul 13, 2021	BUY	$40.9 - $64.9 $1,104 - $1,752	27 Added 450.0%	33 $2,000
Q1 2021 May 03, 2021	SELL	$40.8 - $57.39 $775 - $1,090	-19 Reduced 76.0%	6 $0
Q4 2020 Feb 04, 2021	BUY	$30.79 - $57.2 $585 - $1,086	19 Added 316.67%	25 $1,000
Q3 2020 Oct 26, 2020	SELL	$25.89 - $33.65 $1,035 - $1,346	-40 Reduced 86.96%	6 $0
Q2 2020 Jul 06, 2020	BUY	$24.8 - $38.49 $1,140 - $1,770	46 New	46 $2,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.